Cheaper biotech drugs are headed to the U.S., but analyst Mike Weinstein thinks J&J can manage through some of the challenges.» Read More
On the Pfizer earnings conference call this morning Chairman and CEO Jeff Kindler kicked things off by calling this a "time of great uncertainty in the world economy and capital markets and significant challenges in our industry."
To help investors prepare their portfolios before the weekend, CNBC asked the experts for their best trades now.
Symmetry Medical proves investors can speculate and play defense at the same time.
In Thursday’s Web Extra the traders talk China – now growing at its slowest pace since 2005. Also Pete Najarian has more fun with Pharma.
In Wednesday’s Web Extra Pete Najarian reveals why he thinks the solar trade is starting to turn. Also “if you want to get into drugs” Guy Adami has your play.
The Dow rallied on Wednesday after strong results from Wells Fargo lifted the entire banking sector to it’s biggest one day gain in almost two decades. What's the "Word on the Street?"
The two factors moving the market today were 1) the drop in oil, now down almost 10 percent in two days, and 2) the rally in financials.
The build in oil inventories is providing a rare, two-day drop in oil and a modest boost to stocks midday. Oil is down nearly 10 percent in the past two days. On the decline in oil, airlines are rallying, and energy stocks are dropping notably for the second day in a row.
Abbott Laboratories Wednesday said second-quarter earnings jumped 34 percent, beating its expectations, fueled by sizzling sales of its medical devices, Humira arthritis treatment and other drugs.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
You’ve gotta’ love modern medicine. Not only does it cure stomach upset now it may be the best remedy for what ails your portfolio.
The Dow closed below 11,000 for the first time in two years on Tuesday. What's the "Word on the Street?"
Stocks closed lower following a zig-zag day marked by a plunge in oil and a barrage of statements and news from economic policy makers, and a resurgence for the beaten-down financial sector.
Stocks fell sharply after Federal Reserve Chairman Ben Bernanke issued a dour forecast ahead for the US economy, saying more hard times are on their way that will pose a major challenge to policy makers.
Johnson & Johnson Tuesday posted second-quarter earnings that beat Wall Street expectations, as strong demand for its medical devices and consumer products overshadowed negligible growth of prescription drugs.
Mr. Bernanke's job is to walk the fine line between acknowledging--and defending--the Fed's expanding role in the regulation of investment banking, and not appearing to be coddling excessive risk-takers.
Fed Chairman Ben Bernanke's testimony before a Senate committee takes on even greater importance for Tuesday's markets, now that the Fed and Treasury have promised to backstop mortgage giants Fannie Mae and Freddie Mac.
In Monday’s Web Extra the traders reveal how to play J&J earnings, retail numbers and other events likely to move the market, tomorrow!
Banks are oversold and cheap by historical standards, and while a few that report decent numbers will definitely bounce, it is unlikely to eliminate worries over more capital raising. There's additional worries, as now many are concerned with deterioration in other parts of the banks' portfolios...
To give investors an edge in this volatile market environment, CNBC asked the experts for their best trades now.